

Dyslipidemia in Primary Care:

Addressing Barriers to Optimal Lipid Management

YOU ARE INVITED TO JOIN US...

for an interactive and evidence-based program was developed by leading Canadian experts to address the importance of strict management of low density lipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease as well as provide a timely review of the results of recently completed clinical trials and their applicability to routine clinical practice.

Join us for a group learning session

Date:

Location:

Program Start Time: **Program End Time:**

Speaker(s): **Moderator:**

Registration / Meal Comments:

RSVP:

Lianne Goldin

AGENDA

Dyslipidemia in Primary Care:
Addressing Barriers to Optimal Lipid Management

- **The following topics will be covered during this program:**
  - ✓ Centrality of LDL Cholesterol
  - ✓ Guidelines vs. Real World
  - ✓ Limitations of Current Therapies
  - ✓ Non-Statin Strategies to Reduce LDL-C
  - ✓ PCSK9 Inhibitors: News and Pearls
  - ✓ Improving Outcomes in Our Patients

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

- Recognize the centrality of LDL-C and its cumulative exposure to increased risk of ASCVD events
- Evaluate the limitations of current lipid lowering agents and assess recommendations for lipid lowering agents beyond, or in addition to, statin therapy for high risk patients
- Identify those patients who would benefit from additional therapy beyond statins to reduce CV risk
- Explain the latest clinical data for PCSK9 inhibitors and use effective strategies to integrate the data into clinical care to reduce the risk for CV events
- Appropriately apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics

This Group Learning program has been reviewed by the College of Family Physicians of Canada and is awaiting final certification by the College's Select Chapter from dropdown

This program has received an educational grant and in-kind support from Amgen Canada

Canadian Heart Research Centre